NCT02961101 2026-01-22
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Chinese PLA General Hospital
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT05662397 2025-02-04
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
HotSpot Therapeutics, Inc
Phase 1/2 Active not recruiting
NCT04669899 2024-04-09
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
Jounce Therapeutics, Inc.
Phase 1/2 Completed
NCT03393858 2024-02-07
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Capital Medical University
Phase 1/2 Terminated
NCT03757858 2024-02-07
Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
Capital Medical University
Phase 1/2 Completed
NCT01714739 2023-02-02
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03351231 2020-08-26
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated